We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

14 hedge funds and large institutions have $2.01M invested in Northwest Biotherapeutics, Inc. Common stock in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

7% less funds holding

Funds holding: 15 → 14 (-1)

11% less capital invested

Capital invested by funds: $2.25M → $2.01M (-$240K)

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SL
Sentinus LLC
Illinois
+$247K
2
EFG
Ethos Financial Group
Pennsylvania
+$13.9K

Top Sellers

Rank Fund Capital Flow
1
ECM
Estabrook Capital Management
New York
-$5.49K
2
MSAM
Moloney Securities Asset Management
Missouri
-$813
Name Holding Trade Value Shares
Change 		Change in
Stake
SL
1
Sentinus LLC
Illinois
$1.37M +$247K +395,650 +22%
AA
2
Ancora Advisors
Ohio
$329K – – –
MSAM
3
Moloney Securities Asset Management
Missouri
$178K -$813 -1,300 -0.5%
OCG
4
Opus Capital Group
Ohio
$38K – – –
WJWM
5
Williams Jones Wealth Management
New York
$27.5K – – –
EFG
6
Ethos Financial Group
Pennsylvania
$13.9K +$13.9K +22,200 New
MCM
7
MAI Capital Management
Ohio
$12.5K – – –
LDB
8
Lee, Danner & Bass
Tennessee
$12K – – –
GWI
9
Grace & White Inc
New York
$9.19K – – –
AA
10
AlphaMark Advisors
Kentucky
$9K – – –
AMG
11
Advisors Management Group
Wisconsin
$6K – – –
BC
12
Bartlett & Co
Ohio
$3K – – –
BCWM
13
Bartlett & Co Wealth Management
Ohio
$2.68K – – –
ECM
14
Estabrook Capital Management
New York
– -$5.49K -7,000 Closed

NWBO Hedge Fund Activity: Q1 2023 in Review

14 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2023, worth a combined $2.01M — down 11% from $2.25M a quarter earlier.

Fund positioning in NWBO was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Sentinus LLC, adding an estimated $247K. The largest seller was Estabrook Capital Management, exiting entirely with an estimated $5.49K sold.

  • 14 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2023, down from 15 in Q4 2022.
  • Funds reported $2.01M of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2023, down 11% quarter-over-quarter.
  • 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2023 and 1 closed out, a net change of 0 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2023 was Sentinus LLC, an estimated $247K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2023 was Estabrook Capital Management, an estimated $5.49K sold.

Based on aggregated 13F filings for Q1 2023.